News und Analysen
Canada: TotalEnergies Signs an Agreement to Export 2 Mtpa of LNG for 20 Years From the Ksi Lisims LNG Project
TotalEnergies has signed a Sales and Purchase Agreement (SPA) with Ksi Lisims LNG for the purchase of 2 Mtpa of LNG for 20 years from the future liquefaction plant, subject to the final investment
FIGEAC AÉRO: FIGEAC AÉRO STREGNTHENS ITS POSITION ON A MAJOR NATIONAL SOVEREIGNTY PROGRAMME
Kaufman & Broad SA: ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF 2025, MAY 6TH - VOTING RESULTS
Biogas: TotalEnergies and HitecVision Partner to Pursue the Development of Polska Grupa Biogazowa in Poland
TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) has signed a Sale and Purchase Agreement (SPA) with HitecVision, a Norwegian investment company specializing in energy, for the sale of 50% of Polska
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
Regulatory News:
The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and
Voyageurs du Monde: Notice of conversion of VOYAGEURS DU MONDE convertible bonds
Correction of a release from 12.05.2025 17:37 CET/CEST - Revenue for Q1 2025: 19.7 M€, up +36.5%
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
BILENDI: Q1 2024 revenues up +4.6% at €14.5 million
FIGEAC AÉRO: 10 JUNE 2025: RELEASE OF FULL-YEAR 2024/25 RESULTS
FIGEAC AÉRO: 2024/25 REVENUE TARGET ACHIEVED: €432.3M, REFLECTING 8.1% ORGANIC GROWTH FINANCIAL PERFORMANCE TARGETS REITERATED
Kaufman & Broad SA: DIVIDEND PAYMENT IN RESPECT OF THE FINANCIAL YEAR ENDED NOVEMBER 30, 2024
Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM 2025
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Oman: TotalEnergies and OQEP break ground at Marsa LNG
Under the patronage of His Excellency Eng. Salim bin Nasser Al Aufi, Minister of Energy & Minerals of the Sultanate of Oman, Patrick Pouyanné, Chairman and CEO of TotalEnergies (Paris:TTE)
TP Helps Organizations Adopt and Scale Agentic AI with Two New AI Partnerships
Regulatory News:
Global digital services leader TP (Paris:TEP) today announced partnerships with emerging leaders in agentic artificial intelligence (AI), Ema and Parloa. These partnerships
Teleperformance: Quarterly Information as of March 31, 2025
Regulatory News:
Teleperformance (TP) (Paris:TEP), a global leader in digital business services, recorded revenue of €2,613 million for the first-quarter 2025, up +2.8% as reported and +1.6%
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Median Technologies Reports Full-year 2024 Financial Results
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software
Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software